Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -166.30% | 62.16% | 28.43% | -24.01% | 198.87% |
| Total Depreciation and Amortization | -- | 350.00% | 0.00% | -80.39% | -- |
| Total Amortization of Deferred Charges | 59.95% | -60.09% | 4.68% | 4.74% | 4.80% |
| Total Other Non-Cash Items | -64.20% | -49.82% | -58.73% | 307.28% | 2.07% |
| Change in Net Operating Assets | 155.17% | -638.76% | -288.78% | -149.20% | -210.63% |
| Cash from Operations | -142.04% | 5.68% | -82.79% | 70.89% | 199.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -100.44% | -100.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 110.03% | 83.35% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.60% | 3,276.86% | -124.28% | 8,779.66% | -87.77% |
| Cash from Financing | -108.28% | 682.73% | -110.92% | -3,811.12% | 83.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -120.87% | 100.14% | -88.63% | -479.18% | 616.93% |